title: [Combined therapy for children and adolescents with Ewing tumors (a 25-year experience)].
abstract: A total of 115 children (median age 10.5 years, range 2-17) with Ewing sarcoma family tumors (ESFT) received therapy in N.N. Petrov Institute of Oncology pediatric department from April 1985 till August 2013. These patients were divided into two groups depending on treatment tactics used: patients treated according to modified T9 protocol (n = 64) and patients treated according to EICESS-92 or Euro-Ewing 99 regimens (n = 51). Twenty four patients from the second group with adverse prognostic factors received high-dose chemotherapy with autologous stem cell transplantation. All patients received surgical treatment and/or irradiation for primary tumor local control. Five-year overall and disease-free survival was 39% and 37,9% in the first group. In the second group these values were significantly higher; 55% and 39.5%, accordingly (p = 0.03 and 0.25). All patients from the first group with primary metastatic ESFT died of disease progression, while in the second group OS and DFS reached 45.8% and 28.9%, accordingly. There was a statistically significant correlation between local relapse rate and irradiation dose biological equivalent (in TDF units). The local relapse cumulative rate was minimal (12,6%) in patients receiving 80 TDF.
authors.forename: T V
authors.initials: TV
authors.lastname: Yukhta
authors.forename: Yu A
authors.initials: YA
authors.lastname: Punanov
authors.forename: I V
authors.initials: IV
authors.lastname: Kazantsev
authors.forename: A P
authors.initials: AP
authors.lastname: Malinin
authors.forename: S A
authors.initials: SA
authors.lastname: Safonova
authors.forename: G I
authors.initials: GI
authors.lastname: Gafton
authors.forename: A G
authors.initials: AG
authors.lastname: Gevorgyan
authors.forename: E V
authors.initials: EV
authors.lastname: Morozova
authors.forename: L S
authors.initials: LS
authors.lastname: Zubarovskaya
authors.forename: B V A
authors.initials: BV
authors.lastname: Fanasiev
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012426:Russia; D012512:Sarcoma, Ewing / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult